TA Associates, a global private equity firm, has made a strategic growth investment in Diatech Pharmacogenetics, a pharmacogenetics and cancer medicine diagnostics company.

Diatech produces and distributes genomics testing services to identify gene mutations and genetic differences that are targets of cancer therapies and that influence patient responses to specific treatments. With these tests, Diatech aims to drive the effectiveness of cancer medicine through personalized diagnosis and treatments. As part of the transaction, minority investor Alto Partners will exit its stake in the business. Diatech’s founder and management will retain a majority ownership of the company.

“This strategic partnership with TA will allow us to widen the reach of our existing products and services, while also making a meaningful expansion into international markets,” comments Oliva Alberti, CEO of Diatech.